Hi Guest Login
Home > Service > Oncotype Dx Breast Cancer Test > Banglore
Oncotype Dx is currently the only tumour profiling test incorporated into breast cancer staging. It is used for tumors that are ER-positive, HER2-negative and have not spread to the lymph nodes. The Oncotype Dx test results, combined with other diagnostic data, assist in determining the stage of breast cancer.
Furthermore, it provides valuable insight into: -
Oncotype DX is not a diagnostic test. It does not diagnose cancer. Rather, it is a prognostic and predictive test. That is, it predicts the risk of recurrence of breast cancer in 10 years from the time of first diagnosis and whether chemotherapy is likely to be helpful in addition to hormone therapy. The test compares the expression of 21 genes (16 cancer and 5 reference genes) of the tumor sample through RT-PCR (Reverse Transcriptase Polymerase Chain Reaction). Depending on the activity of the genes, a Recurrence Score (RS) of 0 to 100 is produced.
Oncotype DX Cancer Test in Banglore is best suited for women who: Have Stage I or II invasive breast cancer Have HR-positive and HER2-negative tumors Have no lymph node involvement or only minimal (1-3 nodes) involvement Uncertain about chemotherapy benefit Physicians can order Oncotype DX prior to initiating any systemic treatment, as it identifies if chemotherapy is required or not.
Tumor tissue is typically obtained from the biopsy or surgical specimen (lumpectomy or mastectomy). No further procedure is required. The sample is transported to a central laboratory for examination. Results are usually ready in 3 weeks.
The cost of Oncotype DX cancer test in Banglore ranges between INR 2.5 to 3.5 lakhs, depending on the provider and logistics. Some private health insurance policies may offer partial or full reimbursement. It is advisable to check with your insurance provider in advance.
Even though Oncotype DX is the most well-validated and best-represented genomic test within this category, oncologists might also think about ordering the following tests: MammaPrint – 70-gene signature test to predict risk of breast cancer recurrence. Ki-67 – Protein marker to assess cell proliferation rate. BRCA1/2 or Comprehensive Hereditary Cancer Panel – Particularly for a strong family history of cancer. Yet, Oncotype DX is alone in its prediction of benefit from chemotherapy and is thus the treatment of choice in most eligible situations.
It doesn't apply to HER2-positive or triple-negative breast cancer. It is not suitable for metastatic (Stage IV) breast cancer. It doesn't replace the necessity for conventional staging or receptor testing.
The Oncotype DX report usually consists of three parts:
|
Recurrence Score |
Risk of Recurrence |
Chemotherapy Benefit |
|
0 - 10 |
Very Low |
Not Beneficial |
|
11 - 17 |
Low |
Likely Not Beneficial |
|
18 - 25 |
Intermediate |
Benefit Possible, especially in younger patients |
|
26 - 100 |
High |
Chemotherapy Recommended |
This score is utilized along with clinical factors such as age, tumor size, and grade to inform treatment decisions.
After the test result comes back: Your oncologist will discuss your Recurrence Score with you and discuss your options. If you have a low score, you can be spared chemotherapy and treated with hormonal therapy alone. If your result is high, you and your care team can schedule chemotherapy ahead of time. Either way, the clarity this test brings can significantly minimize anxiety and maximize confidence in your treatment plan.
Making Genomic Testing Accessible At MAX@Home, we know what it's like to be overwhelmed by a diagnosis of cancer. Our clinical coordinators take care of every step of the Oncotype DX test—from sample collection to report delivery—with the greatest care and attention. What we do guarantees the least disruption to your lifestyle while still allowing high-quality decision-making from the most up-to-date scientific evidence.
The information given here is for general purposes only and is not to be used as medical consultation or an alternative to professional advice, diagnosis, or treatment. Always consult your healthcare provider or oncologist to decide the best course of treatment for your specific case.
Read More